Literature DB >> 2351178

A prospective evaluation of OC125 and magnetic resonance imaging in patients with ovarian carcinoma.

A C Perkins1, M C Powell, M L Wastie, I V Scott, A Hitchcock, B S Worthington, E M Symonds.   

Abstract

Eighteen patients with suspected primary or recurrent ovarian carcinoma have been investigated in each case by the assay of serum levels of the antigen CA125, immunoscintigraphy using 131I-OC125 antibody and magnetic resonance imaging using a 0.15 Tesla system. The final diagnosis was confirmed by laparotomy or laparoscopy. Serum levels of CA125 ranged between 5 and 780 units/ml (normal range less than 35). Antibody images and MRI were truly positive in 11 patients, 2 of whom were subsequently found to have bowel tumours. MRI showed greater detail of smaller lesions whilst immunoscintigraphy was more suited to the detection of distant metastases. In 7 patients the antibody images were positive whilst the serum marker levels were normal. This pilot study provides a preliminary comparison of the more recent techniques currently being evaluated for the detection of ovarian carcinoma.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2351178     DOI: 10.1007/bf00842786

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  7 in total

1.  MR imaging: clinical use of the inversion recovery sequence.

Authors:  G M Bydder; I R Young
Journal:  J Comput Assist Tomogr       Date:  1985 Jul-Aug       Impact factor: 1.826

2.  The application of magnetic resonance imaging to gynaecology.

Authors:  M C Powell; E M Symonds; B S Worthington
Journal:  Br J Hosp Med       Date:  1986-06

3.  Physical approach for the reduction of dual radionuclide image subtraction artefacts in immunoscintigraphy.

Authors:  A C Perkins; D R Whalley; J G Hardy
Journal:  Nucl Med Commun       Date:  1984-08       Impact factor: 1.690

4.  Gamma camera emission tomography using radiolabelled antibodies.

Authors:  A C Perkins; D R Whalley; K C Ballantyne; M V Pimm
Journal:  Eur J Nucl Med       Date:  1988

5.  The limitations of the dual radionuclide subtraction technique for the external detection of tumours by radioiodine-labelled antibodies.

Authors:  R J Ott; L J Grey; M A Zivanovic; M A Flower; N G Trott; V Moshakis; R C Coombes; A M Neville; M G Ormerod; J H Westwood; V R McCready
Journal:  Br J Radiol       Date:  1983-02       Impact factor: 3.039

6.  A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer.

Authors:  R C Bast; T L Klug; E St John; E Jenison; J M Niloff; H Lazarus; R S Berkowitz; T Leavitt; C T Griffiths; L Parker; V R Zurawski; R C Knapp
Journal:  N Engl J Med       Date:  1983-10-13       Impact factor: 91.245

7.  Reactivity of a monoclonal antibody with human ovarian carcinoma.

Authors:  R C Bast; M Feeney; H Lazarus; L M Nadler; R B Colvin; R C Knapp
Journal:  J Clin Invest       Date:  1981-11       Impact factor: 14.808

  7 in total
  2 in total

1.  Superimposition of computed tomography and single photon emission tomography immunoscintigraphic images in the pelvis: validation in patients with colorectal or ovarian carcinoma recurrence.

Authors:  J C Liehn; A Loboguerrero; C Pérault; L Demange
Journal:  Eur J Nucl Med       Date:  1992

Review 2.  MUC16 as a novel target for cancer therapy.

Authors:  Abhijit Aithal; Sanchita Rauth; Prakash Kshirsagar; Ashu Shah; Imayavaramban Lakshmanan; Wade M Junker; Maneesh Jain; Moorthy P Ponnusamy; Surinder K Batra
Journal:  Expert Opin Ther Targets       Date:  2018-07-26       Impact factor: 6.902

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.